A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers

Current Oncology

H.T. Lynch⁴  P. Sun³  N. Tung⁶  M. Robson¹  S.A. Narod³  W.D. Foulkes⁷  The Hereditary Breast Cancer Clinical Study Group²  P. Ghadirian^1,10  J. Lubinski⁵  C. Kim–Sing⁸  S.L. Neuhausen⁹  T. Huzarski⁵ 

[1] Memorial Sloan–Kettering Cancer Center;Women’s College Research Institute, University of Toronto;Creighton University;Hereditary Cancer Center, Pomeranian Medical University;Beth Israel Deaconness Hospital;McGill University;BC Cancer Agency;Beckman Research Institute of the City of Hope;CHUM–Hôtel-Dieu

关键词: BRCA1;    BRCA2;    contralateral breast cancer;   

DOI  :  

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Background The risk of breast cancer in carriers of BRCA1 and BRCA2 mutations is influenced by factors other than the genetic mutation itself. Modifying factors include a woman’s reproductive history and family history of cancer. Risk factors are more likely to be present in women with breast cancer than in women without breast cancer, and therefore the risk of cancer in the two breasts should not be independent. It is not clear to what extent modifying factors influence the risk of a first primary or a contralateral breast cancer in BRCA carriers. Methods We conducted a matched case–control study of breast cancer among 3920 BRCA1 or BRCA2 mutation carriers. We asked whether a past history of breast cancer in the contralateral breast was a risk factor for breast cancer. Results After adjustment for age, country of residence, and cancer treatment, a previous cancer of the right breast was found to be a significant risk factor for cancer of the left breast among BRCA1 or BRCA2 carriers (relative risk: 2.1; 95% confidence interval: 1.4 to 3.0; p < 0.0001). Conclusions In a woman with a BRCA1 or BRCA2 mutation who is diagnosed with breast cancer, the risk of cancer in the contralateral breast depends on the first diagnosis. That observation supports the hypothesis that there are important genetic or non-genetic modifiers of cancer risk in BRCA carriers. Discovering risk modifiers might lead to greater personalization of risk assessment and management recommendations for BRCA-positive patients.

【 授权许可】

Unknown